Cis-diamminedichloroplatinum II in advanced urothelial cancer

M. S. Soloway

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46%) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumour (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.

Original languageEnglish (US)
Pages (from-to)716-719
Number of pages4
JournalJournal of Urology
Issue number6
StatePublished - 1978
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Cis-diamminedichloroplatinum II in advanced urothelial cancer'. Together they form a unique fingerprint.

Cite this